Advances in IDH mutation in glioma

Yan Gao, Wenbin Deng, Wenrong Gong, Wenjing Zhang

Research output: Contribution to journalReview article

Abstract

Isocitrate dehydrogenase (IDH) is a key enzyme in the tricarboxylic acid cycle, catalyzing the conversion of isocitric acid to α-ketoglutaric acid (α-KG), using nicotinamide adenine dinucleotide (NAD+)/ nicotinamide adenine dinucleotide phosphate (NADP+) as its cofactor to produce NADH/NADPH. It has been recognized that more than 75% of low grade gliomas (WHO grade II and III) and 90% of secondary glioblastoma multiforme carry IDH gene mutation, with R132H mutation being predominant. IDH mutation may modulate epigenetic characteristics, reprogram cell metabolism, and perturb redox homeostasis of gliomas. Targeted inhibition of mutant IDH in glioma can suppress tumor progression and give birth to the novel anticancer medicines.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalTumor
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Isocitrate Dehydrogenase
Glioma
NADP
NAD
Mutation
Ketoglutaric Acids
Citric Acid Cycle
Glioblastoma
Epigenomics
Oxidation-Reduction
Homeostasis
Parturition
Enzymes
Genes
Neoplasms

Keywords

  • Glioma
  • Isocitrate degydrogenase
  • Mutation
  • Oxidation-reduction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology

Cite this

Advances in IDH mutation in glioma. / Gao, Yan; Deng, Wenbin; Gong, Wenrong; Zhang, Wenjing.

In: Tumor, Vol. 36, No. 1, 01.01.2016, p. 110-115.

Research output: Contribution to journalReview article

Gao, Y, Deng, W, Gong, W & Zhang, W 2016, 'Advances in IDH mutation in glioma', Tumor, vol. 36, no. 1, pp. 110-115. https://doi.org/10.3781/j.issn.1000-7431.2016.55.794
Gao, Yan ; Deng, Wenbin ; Gong, Wenrong ; Zhang, Wenjing. / Advances in IDH mutation in glioma. In: Tumor. 2016 ; Vol. 36, No. 1. pp. 110-115.
@article{61d782d4186f49109c259e48c782b7bc,
title = "Advances in IDH mutation in glioma",
abstract = "Isocitrate dehydrogenase (IDH) is a key enzyme in the tricarboxylic acid cycle, catalyzing the conversion of isocitric acid to {\^I}±-ketoglutaric acid ({\^I}±-KG), using nicotinamide adenine dinucleotide (NAD+)/ nicotinamide adenine dinucleotide phosphate (NADP+) as its cofactor to produce NADH/NADPH. It has been recognized that more than 75{\%} of low grade gliomas (WHO grade II and III) and 90{\%} of secondary glioblastoma multiforme carry IDH gene mutation, with R132H mutation being predominant. IDH mutation may modulate epigenetic characteristics, reprogram cell metabolism, and perturb redox homeostasis of gliomas. Targeted inhibition of mutant IDH in glioma can suppress tumor progression and give birth to the novel anticancer medicines.",
keywords = "Glioma, Isocitrate degydrogenase, Mutation, Oxidation-reduction",
author = "Yan Gao and Wenbin Deng and Wenrong Gong and Wenjing Zhang",
year = "2016",
month = "1",
day = "1",
doi = "10.3781/j.issn.1000-7431.2016.55.794",
language = "English (US)",
volume = "36",
pages = "110--115",
journal = "Tumor",
issn = "1000-7431",
publisher = "Shanghai Jiao Tong University",
number = "1",

}

TY - JOUR

T1 - Advances in IDH mutation in glioma

AU - Gao, Yan

AU - Deng, Wenbin

AU - Gong, Wenrong

AU - Zhang, Wenjing

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Isocitrate dehydrogenase (IDH) is a key enzyme in the tricarboxylic acid cycle, catalyzing the conversion of isocitric acid to α-ketoglutaric acid (α-KG), using nicotinamide adenine dinucleotide (NAD+)/ nicotinamide adenine dinucleotide phosphate (NADP+) as its cofactor to produce NADH/NADPH. It has been recognized that more than 75% of low grade gliomas (WHO grade II and III) and 90% of secondary glioblastoma multiforme carry IDH gene mutation, with R132H mutation being predominant. IDH mutation may modulate epigenetic characteristics, reprogram cell metabolism, and perturb redox homeostasis of gliomas. Targeted inhibition of mutant IDH in glioma can suppress tumor progression and give birth to the novel anticancer medicines.

AB - Isocitrate dehydrogenase (IDH) is a key enzyme in the tricarboxylic acid cycle, catalyzing the conversion of isocitric acid to α-ketoglutaric acid (α-KG), using nicotinamide adenine dinucleotide (NAD+)/ nicotinamide adenine dinucleotide phosphate (NADP+) as its cofactor to produce NADH/NADPH. It has been recognized that more than 75% of low grade gliomas (WHO grade II and III) and 90% of secondary glioblastoma multiforme carry IDH gene mutation, with R132H mutation being predominant. IDH mutation may modulate epigenetic characteristics, reprogram cell metabolism, and perturb redox homeostasis of gliomas. Targeted inhibition of mutant IDH in glioma can suppress tumor progression and give birth to the novel anticancer medicines.

KW - Glioma

KW - Isocitrate degydrogenase

KW - Mutation

KW - Oxidation-reduction

UR - http://www.scopus.com/inward/record.url?scp=84955450321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955450321&partnerID=8YFLogxK

U2 - 10.3781/j.issn.1000-7431.2016.55.794

DO - 10.3781/j.issn.1000-7431.2016.55.794

M3 - Review article

AN - SCOPUS:84955450321

VL - 36

SP - 110

EP - 115

JO - Tumor

JF - Tumor

SN - 1000-7431

IS - 1

ER -